Brendan P Rae, PhD, JD

Innovene Therapeutics is a drug discovery and development company based in New York City founded in 2016. Innovene’s goal is to advance translational research and develop antiviral polyphenol-based therapeutic compounds to treat persistent HPV infection caused by Human Papillomavirus. While these compounds had previously seen limited use due to stability issues and resistance developed in HPV (+) cells, Innovene has successfully resolved these limitations. Our first product is now market-ready. We are a multidisciplinary team combining clinical expertise, R&D competence and business experience that not only fosters innovative approaches to drug development but also ensures that our solutions are effectively tailored to meet patient needs and are successfully introduced into the market. This integrative collaboration is fundamental to Innovene's approach, driving us to develop innovative treatments that are both scientifically advanced and commercially viable. Innovene’s lead drug, INV-015, is an advanced proprietary formulation comprising four naturally occurring compounds in an easy-to-apply intravaginal cream, intended for the treatment of infections with high-risk HPV subtypes. Strategic drug screening has yielded a synergistic mixture of compounds that not only directly inhibit viral replication but also effectively modulate the patient’s immune system to clear HPV-infected cells.